SEC Filings
State Street Holds 4.7% Of Allogene Without Seeking To Influence Control
The September 30 holding covered 16.3 million shares; Allogene released initial autoimmune-treatment trial results Monday.
Allogene Therapeutics (ALLO) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The September 30 holding covered 16.3 million shares; Allogene released initial autoimmune-treatment trial results Monday.
SEC Filings
The cell-therapy developer expects autoimmune-disease results Monday and a lymphoma trial update in mid-2027.
Earnings
A small statistical allowance on the early look tempers hopes of a positive stop, as the CFO retires and enrollment targets end of next year.